Paul Wille

Company: Abeona Therapeutics

Job title: Director - Product Development

Seminars:

Developing a Novel AAV Capsid to Enable Para-retinal Administration Across Multiple Retinal Indications 10:00 am

Demonstrating capsid AAV204 viability in non-human primates to establish the periretinal route of administration for retinal gene therapy Advancing X-linked retinoschisis program with capsid AAV204 data in mice to support progression into large animal studies Platforming the capsid and delivery route combination to expand therapeutic applications across multiple retinal indications including autosomal dominant optic atrophy…Read more

day: Conference Day One